Astellas Pharma US, a subsidiary of the Japanese-based pharmaceutical company Astellas Pharma Inc., is a leading global biopharmaceutical company that focuses on providing innovative medicines in therapeutic areas such as urology, oncology, immunology, nephrology, and neuroscience. Founded in April 2005, Astellas Pharma US has its headquarters in Northbrook, Illinois, a suburb of Chicago. The state-of-the-art headquarters serves as the hub for Astellas’ operations in the Americas, overseeing activities related to research and development, commercialization, and manufacturing of pharmaceutical products.

The company offers a range of products and services, including prescription medicines, over-the-counter drugs, and medical devices. Some of its notable products include Xtandi (enzalutamide) for the treatment of advanced prostate cancer, Myrbetriq (mirabegron) for overactive bladder, and Prograf (tacrolimus) for immunosuppressive therapy in organ transplantation. With a global presence, Astellas operates in more than 50 countries across the Americas, Europe, Asia, Oceania, and Africa.

The company has established several subsidiaries, joint ventures, and partnerships to expand its reach and capabilities. These include Astellas Pharma Europe Ltd., Astellas Pharma Asia Pacific Ltd., and a joint venture with Luye Pharma Group called Astellas Luye Pharmaceutical. In terms of market position, Astellas Pharma is considered one of the top 20 pharmaceutical companies globally.

It has achieved significant success and recognition, including being named one of the top 100 global innovators by Clarivate Analytics. Astellas has a strong track record of sales growth, with its global revenue reaching approximately $12 billion in fiscal year 2020. The company has made notable strides in its growth and innovation efforts.

For instance, in 2020, Astellas acquired Audentes Therapeutics, a company specialized in developing gene therapies for rare diseases, to strengthen its position in the field of genetic medicines. Currently, Astellas Pharma US continues to advance its pipeline of innovative medicines while focusing on patient-centric approaches and sustainable business practices. In recent updates, the company has been actively involved in COVID-19 research and development efforts, collaborating with partners to explore potential treatments and vaccines.

Overall, Astellas Pharma US has established itself as a prominent player in the pharmaceutical industry, leveraging its global presence, diverse product portfolio, and commitment to scientific innovation to improve the lives of patients worldwide